Early Experience of High-dose Intravenous Mycobacterium w in Critically Ill Patients of COVID-19

BACKGROUND: Immune dysregulation is one of the main reasons for mortality and morbidity in coronavirus disease 2019 (COVID-19). Mycobacterium w (Mw) is recently approved for gram-negative sepsis. Moreover, it is also found effective in COVID-19 patients in previous studies. The traditional route of...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Parth Sudhendu, Patel, Sudhendu, Shah, Vidhi, Aswani, Varsha, Narwaria, Mahendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664032/
https://www.ncbi.nlm.nih.gov/pubmed/34963729
http://dx.doi.org/10.5005/jp-journals-10071-23963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664032/
https://www.ncbi.nlm.nih.gov/pubmed/34963729
http://dx.doi.org/10.5005/jp-journals-10071-23963

Ejemplares similares